Back to Research Home
PFEPfizer Inc
Health Care · Pharmaceuticals · Large
$30.03−1.28%
As of 23 Oct 2026Mkt cap $165B
Stage 13
AVOID
Fundamentals
36.2/75
Technical
4.7/15
Independent
40.9/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- +5.7%
- 3M
- +21.7%
- 6M
- +11.2%
- 1Y
- +21.5%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 39.5xHist median 18.5x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 15.6x
- FCF yield
- 6.4%
Quality
- ROIC
- —
- Operating margin
- 31.8%
- FCF margin
- 14.5%
- Current ratio
- 1.2x
Growth
- Revenue growth
- −1.6%Latest FY YoY
- Revenue CAGR
- −6.3%
- EPS CAGR
- −22.9%
- FCF CAGR
- −25.8%
Capital
- Share-count trend
- +0.0%3Y annualised
- Net debt
- $66.3B5.7x OCF
Annual trend
- CAGR 2021–2025
- −6.3%
- Latest · 2025
- $63B
- YoY
- −1.6%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- WATCH · CURRENT
Key takeaway
2026 guidance improved and oncology/pipeline catalysts continue, but the coming loss-of-exclusivity burden still requires new products and Seagen assets to replace a large revenue base; thesis remains credible but conditional.
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-03
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded